Jazz Pharmaceuticals to pay $20 million in penalties and compensation

Jazz Pharmaceuticals will pay $20 million in penalties and victim compensation to resolve criminal and civil investigations into illegal marketing by its Orphan Medical wholly owned subsidiary. The US Attorney for New York's Eastern District says Orphan pled guilty to felony misbranding for illegal promotion of Xyrem for unapproved uses.

You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.